By Jonathan Gardner
Published August 20, 2026
In a significant development for the rare disease community, the U.S. pharmaceutical landscape for Fibrodysplasia Ossificans Progressiva (FOP)—a debilitating condition characterized by the transformation of soft tissue into bone—has been fundamentally altered. Regeneron Pharmaceuticals has secured approval for Pasatru (garetosmab), setting the stage for a high-stakes commercial showdown with Ipsen’s Sohonos. This launch arrives at a critical juncture for Regeneron, which is seeking to diversify its revenue streams amidst mounting pressure on its flagship ophthalmology franchise.
Main Facts: The Arrival of Pasatru
Pasatru (garetosmab) is an antibody therapeutic designed to address the underlying biological mechanism of FOP. By selectively blocking the activity of Activin A, a protein identified as a primary driver of the excessive, heterotopic ossification that plagues patients, Pasatru aims to halt the progression of bone growth in soft tissues.
Regeneron has announced a premium pricing strategy for the therapy, reflecting the complexities of manufacturing and the ultra-rare patient population. The drug carries an average annual, per-patient list price of approximately $1.4 million. Because the dosage is calculated based on weight—ranging from 3 to 10 milligrams per kilogram—the actual cost per patient can fluctuate between $693,000 and $2.1 million annually. This pricing structure places Pasatru among the most expensive therapeutic options in the rare disease space, a category often referred to as "orphan drugs."
Chronology of a Rare Disease Battle
The history of pharmacological intervention in FOP has been brief and fraught with challenges. For decades, patients had no approved treatments, relying solely on supportive care and the management of "flare-ups"—the inflammatory events that precede the hardening of muscle and connective tissue into bone.
- 2023: Ipsen received FDA approval for Sohonos (palovarotene), the first-ever treatment for FOP. The approval was met with both relief and skepticism, as regulatory documents revealed concerns from FDA scientists regarding the drug’s modest impact on heterotopic ossification and a potential increase in inflammatory flare-ups compared to placebo groups.
- 2024: Ipsen reported significant commercial headwinds. Facing slower-than-expected uptake, the company recorded an impairment charge of 279 million euros, signaling that the market reality for FOP therapies was far more difficult than initial projections suggested.
- 2026 (First Half): Sohonos continued to struggle, recording sales of just 21 million euros ($24 million), a figure that remained stagnant compared to the same period in 2025.
- August 20, 2026: The FDA grants approval to Regeneron’s Pasatru, introducing a new, potentially more efficacious mechanism of action to a market that has yet to see a blockbuster therapeutic success.
Supporting Data: Comparative Efficacy and Safety
The entry of Pasatru creates an immediate point of comparison with the existing standard of care. While no head-to-head clinical trials have been conducted to date, the clinical profiles of the two drugs offer starkly different narratives.
Clinical data for Pasatru suggests a robust inhibition of Activin A, which experts believe may provide a more comprehensive blockade of the pathways leading to bone formation. Conversely, Sohonos acts as a retinoic acid receptor gamma agonist. Since its 2023 debut, questions have persisted regarding its safety profile, particularly concerning the observed inflammatory responses in clinical trials.
The commercial failure of Sohonos to gain traction—evidenced by the 279 million euro impairment charge—reflects not just the rarity of the disease, but the hesitancy of physicians and payers to adopt a therapy with questionable safety margins and limited clinical impact. Regeneron is banking on the fact that Pasatru’s antibody-based approach provides a more targeted, and potentially more effective, intervention that will overcome the inertia currently stifling the FOP market.
Official Responses: Community and Industry Sentiment
The patient advocacy community has largely hailed the arrival of a second option. For those living with FOP, the prospect of having a choice in therapy is a monumental shift.
"This approval is monumental for our community, providing a vital new therapy that can have a significant impact on the life of someone with FOP," stated Michelle Davis, executive director of the International FOP Association. The organization has long advocated for increased investment in the space, noting that the physical and psychological toll of the disease requires multiple therapeutic modalities to ensure that every patient finds a regimen that fits their specific needs.
Regeneron, for its part, is positioning Pasatru as a centerpiece of its commitment to high-science innovation. However, the company has remained cautious in its public statements, focusing on the clinical data that supported the drug’s regulatory path rather than projecting immediate, explosive growth.
Implications: A Crossroads for Regeneron
The launch of Pasatru is arguably as important for Regeneron’s corporate strategy as it is for the FOP patient community. The company is currently navigating a period of significant transition and uncertainty.
The Eylea Challenge
Regeneron’s primary engine for growth has long been Eylea, its blockbuster eye drug. However, that franchise is currently under siege. The expiration of patent protections has opened the door for biosimilar competition, which is expected to erode market share and pricing power. While Regeneron launched a high-dose version of Eylea to combat this, early results have been underwhelming. Recent earnings reports indicated that the high-dose version has not met the aggressive growth targets set by Wall Street analysts.
R&D Setbacks
Adding to the pressure, the company’s R&D pipeline has faced recent hurdles. A promising cancer immunotherapy candidate, Fianlimab, recently missed its primary endpoint in a key clinical trial for melanoma. This miss has forced investors to look more closely at the company’s secondary assets to determine where future growth will materialize.
The Rare Disease Strategy
Pasatru represents a shift toward a high-value, low-volume commercial model. By focusing on ultra-rare indications, Regeneron is attempting to insulate itself from the "commoditization" risks seen in the eye-care market. However, the "orphan drug" model is not without risks. High price points—such as the $1.4 million average for Pasatru—invite intense scrutiny from payers, government regulators, and pharmacy benefit managers.
If Pasatru succeeds where Sohonos failed, it could provide a blueprint for Regeneron to navigate the next decade of its corporate life. If it falters, it may signal that even the most innovative science cannot overcome the structural barriers of small patient populations and skeptical reimbursement environments.
Conclusion
The approval of Pasatru is a milestone in the treatment of FOP, offering a potential lifeline to patients who have been underserved for years. Yet, as the drug moves from clinical approval to the real-world market, it does so against a backdrop of intense corporate pressure. For Regeneron, Pasatru is more than just a therapy; it is a test of the company’s ability to pivot toward high-value, rare-disease therapeutics at a time when its traditional powerhouses are losing their dominance. As clinicians begin to evaluate the drug’s effectiveness in the real world, the industry will be watching closely to see if Pasatru can truly redefine the standard of care in a market that has proven remarkably difficult to conquer.
